Friday, 16 October 2026European Markets

ADC SIIC Stock Is 16% Up In The Last 5 Sessions

Loading stream...

(vianews) - shares of adc siic (cac 40: aldv.pa) jumped by a staggering 16.67% in 5 sessions from €0.06 to €0.07 at 14:37 est on tuesday, following the last session's upward trend. cac 40 is dropping 0.26% to €7,284.73, following the last session's downward trend.

adc siic's last close was €0.07, 27.78% below its 52-week high of €0.09.

about adc siic

alliance developpement capital siic (adc siic) is a publicly owned real estate investment firm. the firm specializes in owning and managing residential real estate properties. it primarily invests in properties in paris and its suburbs. the firm was formerly known as ad capital sa. alliance developpement capital is based in saint-josse-ten-noode, belgium.

earnings per share

as for profitability, adc siic has a trailing twelve months eps of €-0.01.

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is negative -2.85%.

yearly top and bottom value

adc siic's stock is valued at €0.07 at 14:37 est, way under its 52-week high of €0.09 and way higher than its 52-week low of €0.06.

moving average

adc siic's worth is higher than its 50-day moving average of €0.07 and under its 200-day moving average of €0.07.

stock price classification

according to the stochastic oscillator, a useful indicator of overbought and oversold conditions, adc siic's stock is considered to be oversold (<=20).

volatility

adc siic's last week, last month's, and last quarter's current intraday variation average was a positive 8.33%, a negative 1.72%, and a positive 11.16%.

adc siic's highest amplitude of average volatility was 8.33% (last week), 14.64% (last month), and 11.16% (last quarter).

more news about adc siic (aldv.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com